Acceleration Therapeutics, a division of Non-Invasive Monitoring Systems, Inc. (NIMS) (OTCBB:NIMU), announced that the AT-101 was used to prove that the cardioprotective effect associated with the AT-101 is due in part to the release of beneficial prostaglandins from the inner lining of the blood vessels.
The study, using a model of experimental cardiopulmonary resuscitation (CPR), was lead by Dr. Tony Adams of Mt. Sinai Medical Center and Miami Heart Research Institute Miami Beach. It was presented in New Orleans during the annual meeting of the American Heart Association on November 7-10, 2004.
Dr. Adams stated: "We knew that both nitric oxide and prostaglandins were released with the AT-101 in normal animals and this study now shows the importance of prostaglandins in the beneficial cardiac effects of AT-101 CPR. This suggests that the AT-101 might have a complementary or stand-alone role in human CPR in the future."
These investigators previously showed that Acceleration Therapeutics' modified AT-101 device produced better heart function after cardiopulmonary resuscitation in an animal model of ventricular fibrillation than standard closed chest compression CPR.
The AT-101 is a comfortable platform, mounted on a hospital-like patient gurney, that moves the body repetitively in a back and forth motion from head to foot, similar to the movement used to comfort a child in a baby carriage but at a more rapid pace. It is currently listed with the FDA as a Class I (exempt) powered exercise device intended as an aid to improve the circulation and joint mobility. Medicare and insurance companies under CPT 97710, Therapeutic Exercises, reimburse its application in most chronic neurological and rheumatologic diseases as well as acute soft tissue and bone injuries.
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: The Statements which are not historical facts contained in this press release are forward-looking statements that involve certain risks and uncertainties including but not limited to risks associated with the uncertainty of future financial results, additional financing requirements, development of new products, government approval processes, the impact of competitive products or pricing, technological changes, the effect of economic conditions and other uncertainties detailed in the Company's filings with the Securities and Exchange Commission.